What is the long-term trend for BioCryst Pharmaceuticals's available for sale investments?

Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's available for sale investments has grown at a 21.4% compound annual growth rate (CAGR), from $137.62M to $246.18M.

BioCryst Pharmaceuticals BCRX Available for sale investments

Available for sale investments at other companies

Ionis PharmaceuticalsIONS

——

BridgeBio PharmaBBIO

——

Agios PharmaceuticalsAGIO

——

PrecigenPGEN

——

Regeneron PharmaceuticalsREGN

——

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's available for sale investments?: BioCryst Pharmaceuticals (BCRX) reported available for sale investments of $87.38M in Q1 2026.
How has BioCryst Pharmaceuticals's available for sale investments changed year-over-year?: BioCryst Pharmaceuticals's available for sale investments decreased by 58.5% year-over-year, from $210.45M to $87.38M.
What is the long-term trend for BioCryst Pharmaceuticals's available for sale investments?: Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's available for sale investments has grown at a 21.4% compound annual growth rate (CAGR), from $137.62M to $246.18M.